Oxidative stress in Alzheimer's disease

Pathophysiology

Volumn 13, Issue 3, 2006, Pages 195-208

  Chauhan, Ved ^a   Chauhan, Abha ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Aging; Alzheimer's disease; Amyloid beta protein; Lipid peroxidation; Mitochondrial dysfunction; Neurofibrillary tangles; Oxidative stress; Presenilins; Proteases

Indexed keywords

ACETYLCARNITINE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; APOLIPOPROTEIN E; ASCORBIC ACID; BETA CAROTENE; CURCUMIN; ELLAGIC ACID; FLAVONOID; GINKGO BILOBA EXTRACT; GOSSYPINE; IDEBENONE; MELATONIN; MICROTUBULE ASSOCIATED PROTEIN; NARINGENIN; PRESENILIN 1; PROTEINASE; PYRIDOXINE; TAU PROTEIN; TERPENOID DERIVATIVE; THIOCTIC ACID; UBIQUINONE;

AGING; ALZHEIMER DISEASE; BRAIN INJURY; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GINKGO BILOBA; HUMAN; HYPERCHOLESTEROLEMIA; KNOCKOUT MOUSE; LEARNING DISORDER; LIPID PEROXIDATION; MEMORY DISORDER; NERVE CELL LESION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUROTOXICITY; NITROSATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 33745727582     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2006.05.004     Document Type: Review

References (168)

1. Wisniewski H.M., Wegiel J., and Kotula L. Some neuropathology aspects of Alzheimer's disease and its relevance to other disciplines. Neuropathol. Appl. Neurobiol. 22 (1996) 3-11
2. Glenner G.G. Alzheimer's disease. The commonest form of amyloidosis. Arch. Pathol. Lab. Med. 107 (1983) 281-282
3. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 4245-4249
4. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., and Swindlehurst C. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 (1992) 325-327
5. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., and Schenk D.B. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61 (1993) 1965-1968
6. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., and Teplow D.B. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359 (1992) 322-325
7. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., and Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 4913-4917
8. Kopke E., Tung Y.C., Shaikh S., Alonso A.C., Iqbal K., and Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 268 (1993) 24374-24384
9. Alonso A., Zaidi T., Novak M., Grundke-Iqbal I., and Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6923-6928
10. Alonso A.C., Zaidi T., Grundke-Iqbal I., and Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 5562-5566
11. Iqbal K., Grundke-Iqbal I., Zaidi T., Merz P.A., Wen G.Y., Shaikh S.S., Wisniewski H.M., Alafuzoff I., and Winblad B. Defective brain microtubule assembly in Alzheimer's disease. Lancet 2 (1986) 421-426
12. Lee V.M., Balin B.J., Otvos Jr. L., and Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 251 (1991) 675-678
13. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., and Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325 (1987) 733-736
14. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., and Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999) 735-741
15. Sastre M., Steiner H., Fuchs K., Capell A., Multhaup G., Condron M.M., Teplow D.B., and Haass C. Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep. 2 (2001) 835-841
16. Yu C., Kim S.H., Ikeuchi T., Xu H., Gasparini L., Wang R., and Sisodia S.S. Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma. Evidence for distinct mechanisms involved in gamma-secretase processing of the APP and Notch1 transmembrane domains. J. Biol. Chem. 276 (2001) 43756-43760
17. Vardy E.R., Catto A.J., and Hooper N.M. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol. Med. 11 (2005) 464-472
18. Brown J. Mutations in amyloid precursor protein gene and Alzheimer's disease. Lancet 337 (1991) 923-924
19. Hutton M., and Hardy J. The presenilins and Alzheimer's disease. Hum. Mol. Genet. 6 (1997) 1639-1646
20. Myers A.J., and Goate A.M. The genetics of late onset Alzheimer's disease. Curr. Opin. Neurol. 14 (2001) 433-440
21. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., and van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278 (1997) 1349-1356
22. Hardy J. Molecular genetics of Alzheimer's disease. Acta Neurol. Scand. Suppl. 165 (1996) 13-17
23. Bandopadhyay U., Dipak D., and Banerjee R.K. Reactive oxygen species: oxidative damage and pathogenesis. Curr. Sci. 77 (1999) 658-666
24. Arlt S., Beisiegel U., and Kontush A. Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease. Curr. Opin. Lipidol. 13 (2002) 289-294
25. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11 (1956) 298-300
26. Harman D. Free radical theory of aging. Triangle 12 (1973) 153-158
27. Sohal R.S., and Orr W.C. In: Esser K., and Martins G.M. (Eds). Molecular Aspects of Aging (1995), J. Wiley, Chichester, England 109-127
28. Apelt J., Bigl M., Wunderlich P., and Schliebs R. Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int. J. Dev. Neurosci. 22 (2004) 475-484
29. Kim H.C., Yamada K., Nitta A., Olariu A., Tran M.H., Mizuno M., Nakajima A., Nagai T., Kamei H., Jhoo W.K., Im D.H., Shin E.J., Hjelle O.P., Ottersen O.P., Park S.C., Kato K., Mirault M.E., and Nabeshima T. Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant systems in vivo. Neuroscience 119 (2003) 399-419
30. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., and Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2070-2075
31. Park L., Anrather J., Forster C., Kazama K., Carlson G.A., and Iadecola C. Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J. Cereb. Blood Flow Metab. 24 (2004) 334-342
32. Jhoo J.H., Kim H.C., Nabeshima T., Yamada K., Shin E.J., Jhoo W.K., Kim W., Kang K.S., Jo S.A., and Woo J.I. Beta-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav. Brain Res. 155 (2004) 185-196
33. Sultana R., Ravagna A., Mohmmad-Abdul H., Calabrese V., and Butterfield D.A. Ferulic acid ethyl ester protects neurons against amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J. Neurochem. 92 (2005) 749-758
34. Dikalov S.I., Vitek M.P., and Mason R.P. Cupric-amyloid beta peptide complex stimulates oxidation of ascorbate and generation of hydroxyl radical. Free Radic. Biol. Med. 36 (2004) 340-347
35. Ali F.E., Separovic F., Barrow C.J., Cherny R.A., Fraser F., Bush A.I., Masters C.L., and Barnham K.J. Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. J. Pept. Sci. 11 (2005) 353-360
36. Schuessel K., Schafer S., Bayer T.A., Czech C., Pradier L., Muller-Spahn F., Muller W.E., and Eckert A. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol. Dis. 18 (2005) 89-99
37. Mohmmad A.H., Wenk G.L., Gramling M., Hauss-Wegrzyniak B., and Butterfield D.A. APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease. Neurosci. Lett. 368 (2004) 148-150
38. Mazur-Kolecka B., Kowal D., Sukontasup T., Dickson D., and Frackowiak J. The effect of oxidative stress on accumulation of apolipoprotein E3 and E4 in a cell culture model of beta-amyloid angiopathy (CAA). Brain Res. 983 (2003) 48-57
39. Behl C. Oxidative stress in Alzheimer's disease: implications for prevention and therapy. Subcell. Biochem. 38 (2005) 65-78
40. Um M.Y., Choi W.H., Aan J.Y., Kim S.R., and Ha T.Y. Protective effect of Polygonum multiflorum Thunb on amyloid beta-peptide 25-35 induced cognitive deficits in mice. J. Ethnopharmacol. 104 (2006) 144-148
41. Mohmmad A.H., and Butterfield D.A. Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease. Biochim. Biophys. Acta 1741 (2005) 140-148
42. Yao J., Petanceska S.S., Montine T.J., Holtzman D.M., Schmidt S.D., Parker C.A., Callahan M.J., Lipinski W.J., Bisgaier C.L., Turner B.A., Nixon R.A., Martins R.N., Ouimet C., Smith J.D., Davies P., Laska E., Ehrlich M.E., Walker L.C., Mathews P.M., and Gandy S. Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits. J. Neurochem. 90 (2004) 1011-1018
43. Kirkitadze M.D., and Kowalska A. Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. Acta Biochim. Pol. 52 (2005) 417-423
44. 2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp. Neurol. 180 (2003) 144-155
45. Coyle J.T., Price D.L., and Delong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219 (1983) 1184-1190
46. Kimura M., Komatsu H., Ogura H., and Sawada K. Comparison of donepezil and memantine for protective effect against amyloid-beta(1-42) toxicity in rat septal neurons. Neurosci. Lett. 391 (2005) 17-21
47. Qi X.L., Xiu J., Shan K.R., Xiao Y., Gu R., Liu R.Y., and Guan Z.Z. Oxidative stress induced by beta-amyloid peptide(1-42) is involved in the altered composition of cellular membrane lipids and the decreased expression of nicotinic receptors in human SH-SY5Y neuroblastoma cells. Neurochem. Int. 46 (2005) 613-621
48. Cecchi C., Fiorillo C., Sorbi S., Latorraca S., Nacmias B., Bagnoli S., Nassi P., and Liguri G. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic. Biol. Med. 33 (2002) 1372-1379
49. Stadtman E.E., and Berlett B.S. Reactive oxygen-mediated protein oxidation in aging and disease. Chem. Res. Toxicol. 10 (1997) 485-494
50. Boyd-Kimball D., Sultana R., Poon H.F., Lynn B.C., Casamenti F., Pepeu G., Klein J.B., and Butterfield D.A. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 132 (2005) 313-324
51. Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., and Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem. 82 (2002) 1524-1532
52. Korolainen M.A., Goldsteins G., Alafuzoff I., Koistinaho J., and Pirttila T. Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis 23 (2002) 3428-3433
53. Wiseman H., and Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J. 313 (1996) 17-29
54. Lyras L., Cairns N.J., Jenner A., Jenner P., and Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 68 (1997) 2061-2069
55. Gabbita S.P., Lovell M.A., and Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 71 (1998) 2034-2040
56. Markesbery W.R., and Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9 (1999) 133-146
57. Lovell M.A., Gabbita S.P., and Markesbery W.R. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J. Neurochem. 72 (1999) 771-776
58. Duker N.J., Sperling J., Soprano K.J., Druin D.P., Davis A., and Ashworth R. Beta-amyloid protein induces the formation of purine dimers in cellular DNA. J. Cell Biochem. 81 (2001) 393-400
59. Marcus D.L., Strafaci J.A., and Freedman M.L. Differential neuronal expression of manganese superoxide dismutase in Alzheimer's disease. Med. Sci. Monit. 12 (2005) 8-14
60. Perrin R., Briancon S., Jeandel C., Artur Y., Minn A., Penin F., and Siest G. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: a case-control study. Gerontology 36 (1990) 306-313
61. Zemlan F.P., Thienhaus O.J., and Bosmann H.B. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. Brain Res. 476 (1989) 160-162
62. De Leo M.E., Borrello S., Passantino M., Palazzotti B., Mordente A., Daniele A., Filippini V., Galeotti T., and Masullo C. Oxidative stress and overexpression of manganese superoxide dismutase in patients with Alzheimer's disease. Neurosci. Lett. 250 (1998) 173-176
63. Snaedal J., Kristinsson J., Gunnarsdottir S., Olafsdottir, Baldvinsson M., and Johannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. A case-control study. Dement. Geriatr. Cogn. Disord. 9 (1998) 239-242
64. Margaglione M., Garofano R., Cirillo F., Ruocco A., Grandone E., Vecchione G., Milan G., Di Minno G., De Blasi A., and Postiglione A. Cu/Zn superoxide dismutase in patients with non-familial Alzheimer's disease. Aging 7 (1995) 49-54
65. Chen Z., Duan R.S., Lepecheur M., Paly E., London J., and Zhu J. SOD-1 inhibits FAS expression in cortex of APP transgenic mice. Apoptosis 10 (2005) 499-502
66. Turner B.J., Li Q.X., Laughton K.M., Masters C.L., Lopes E.C., Atkin J.D., and Cheema S.S. Brain beta-amyloid accumulation in transgenic mice expressing mutant superoxide dismutase 1. Neurochem. Res. 29 (2004) 2281-2286
67. Leutner S., Czech C., Schindowski K., Touchet N., Eckert A., and Muller W.E. Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neurosci. Lett. 292 (2000) 87-90
68. Li F., Calingasan N.Y., Yu F., Mauck W.M., Toidze M., Almeida C.G., Takahashi R.H., Carlson G.A., Flint B.M., Lin M.T., and Gouras G.K. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J. Neurochem. 89 (2004) 1308-1312
69. Reid M., and Jahoor F. Glutathione in disease. Curr. Opin. Clin. Nutr. Metab. Care 4 (2001) 65-71
70. Cecchi C., Latorraca S., Sorbi S., Iantomasi T., Favilli F., Vincenzini M.T., and Liguri G. Gluthatione level is altered in lymphoblasts from patients with familial Alzheimer's disease. Neurosci. Lett. 275 (1999) 152-154
71. Crack P.J., Cimdins K., Ali U., Hertzog P.J., and Iannello R.C. Lack of glutathione peroxidase-1 exacerbates Abeta-mediated neurotoxicity in cortical neurons. J. Neural Trans. 113 (2006) 645-657
72. Lovell M.A., Ehmann W.D., Butler S.M., and Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45 (1995) 1594-1601
73. Sulkava R., Nordberg U.R., Erkinjuntti T., and Westermarck T. Erythrocyte glutathione peroxidase and superoxide dismutase in Alzheimer's disease and other dementias. Acta Neurol. Scand. 73 (1986) 487-489
74. Pappolla M.A., Smith M.A., Bryant-Thomas T., Bazan N., Petanceska S., Perry G., Thal L.J., Sano M., and Refolo L.M. Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. Free Radic. Biol. Med. 33 (2002) 173-181
75. Nelson T.J., and Alkon D.L. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J. Biol. Chem. 280 (2005) 7377-7387
76. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., van Duijn C.N., Van Broeckhoven C., and Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349 (1997) 151-154
77. Kivipelto M., Helkala E.L., Hanninen T., Laakso M.P., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., and Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 56 (2001) 1683-1689
78. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
79. Refolo L.M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., Duff K., and Pappolla M.A. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7 (2000) 321-331
80. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., Von Bergmann K., Hennerici M., Beyreuther K., and Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5856-5861
81. Wisniewski H.M., and Wegiel J. Migration of perivascular cells into the neuropil and their involvement in beta-amyloid plaque formation. Acta Neuropathol. (Berl.) 85 (1993) 586-595
82. D'Andrea M.R., Cole G.M., and Ard M.D. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging 25 (2004) 675-683
83. Thatcher G.R., Bennett B.M., and Reynolds J.N. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res. 2 (2005) 171-182
84. Thorns V., Hansen L., and Masliah E. nNOS expressing neurons in the entorhinal cortex and hippocampus are affected in patients with Alzheimer's disease. Exp. Neurol. 150 (1998) 14-20
85. Zhang Y.J., Xu Y.F., Liu Y.H., Yin J., and Wang J.Z. Nitric oxide induces tau hyperphosphorylation via glycogen synthase kinase-3beta activation. FEBS Lett. 579 (2005) 6230-6236
86. Keil U., Bonert A., Marques C.A., Strosznajder J.B., Muller-Spahn F., Muller W.E., and Eckert A. Elevated nitric oxide production mediates beta-amyloid-induced mitochondria failure. Pol. J. Pharmacol. 56 (2004) 631-634
87. Keil U., Bonert A., Marques C.A., Scherping I., Weyermann J., Strosznajder J.B., Muller-Spahn F., Haass C., Czech C., Pradier L., Muller W.E., and Eckert A. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J. Biol. Chem. 279 (2004) 50310-50320
88. Jang J.H., and Surh Y.J. AP-1 mediates beta-amyloid-induced iNOS expression in PC12 cells via the ERK2 and p38 MAPK signaling pathways. Biochem. Biophys. Res. Commun. 331 (2005) 1421-1428
89. Hu J., and El Fakahany E.E. Beta-amyloid 25-35 activates nitric oxide synthase in a neuronal clone. Neuroreport 4 (1993) 760-762
90. Venturini G., Colasanti M., Persichini T., Fioravanti E., Ascenzi P., Palomba L., Cantoni O., and Musci G. Beta-amyloid inhibits NOS activity by subtracting NADPH availability. FASEB J. 16 (2002) 1970-1972
91. Vitek M.P., Snell J., Dawson H., and Colton C.A. Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. Biochem. Biophys. Res. Commun. 240 (1997) 391-394
92. Ii M., Sunamoto M., Ohnishi K., and Ichimori Y. Beta-amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity. Brain Res. 720 (1996) 93-100
93. DiCiero M.M., de Bruin V.M., Vale M.R., and Viana G.S. Lipid peroxidation and nitrite plus nitrate levels in brain tissue from patients with Alzheimer's disease. Gerontology 46 (2000) 179-184
94. Chauhan A., Pirttila T., Mehta P., Chauhan V.P., and Wisniewski H.M. Effect of cerebrospinal fluid from normal and Alzheimer's patients with different apolipoprotein E phenotypes on in vitro aggregation of amyloid beta-protein. J. Neurol. Sci. 141 (1996) 54-58
95. Chauhan A., Chauhan V.P., Rubenstein R., Wegiel J., and Wisniewski H.M. Media from rhabdomyosarcoma and neuroblastoma cell cultures stimulate in vitro aggregation and fibrillization of amyloid beta-protein. Neurochem. Res. 22 (1997) 227-232
96. Chauhan A., Pirttila T., Chauhan V.P., Mehta P., and Wisniewski H.M. Aggregation of amyloid beta-protein as function of age and apolipoprotein E in normal and Alzheimer's serum. J. Neurol. Sci. 154 (1998) 159-163
97. Ray I., Chauhan A., Wegiel J., and Chauhan V.P. Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res. 853 (2000) 344-351
98. Chauhan V.P., Chauhan A., and Wegiel J. Fibrillar amyloid beta-protein forms a membrane-like hydrophobic domain. Neuroreport 12 (2001) 587-590
99. Iversen L.L., Mortishire-Smith R.J., Pollack S.J., and Shearman M.S. The toxicity in vitro of beta-amyloid protein. Biochem. J. 311 (1995) 1-16
100. Lorenzo A., and Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 12243-12247
101. Lorenzo A., and Yankner B.A. Amyloid fibril toxicity in Alzheimer's disease and diabetes. Ann. N. Y. Acad. Sci. 777 (1996) 89-95
102. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic. Res. 36 (2002) 1307-1313
103. Snyder S.W., Ladror U.S., Wade W.S., Wang G.T., Barrett L.W., Matayoshi E.D., Huffaker H.J., Krafft G.A., and Holzman T.F. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J. 67 (1994) 1216-1228
104. Cardoso S.M., Santana I., Swerdlow R.H., and Oliveira C.R. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J. Neurochem. 89 (2004) 1417-1426
105. Zhu X., Smith M.A., Perry G., and Aliev G. Mitochondrial failures in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 19 (2004) 345-352
106. Castellani R.J., Honda K., Zhu X., Cash A.D., Nunomura A., Perry G., and Smith M.A. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res. Rev. 3 (2004) 319-326
107. Abramov A.Y., Canevari L., and Duchen M.R. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J. Neurosci. 24 (2004) 565-575
108. Tamagno E., Parola M., Guglielmotto M., Santoro G., Bardini P., Marra L., Tabaton M., and Danni O. Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radic. Biol. Med. 35 (2003) 45-58
109. Simonian N.A., and Coyle J.T. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 83-106
110. Tamagno E., Parola M., Bardini P., Piccini A., Borghi R., Guglielmotto M., Santoro G., Davit A., Danni O., Smith M.A., Perry G., and Tabaton M. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 92 (2005) 628-636
111. Tong Y., Zhou W., Fung V., Christensen M.A., Qing H., Sun X., and Song W. Oxidative stress potentiates BACE1 gene expression and Abeta generation. J. Neural Trans. 112 (2005) 455-469
112. Celsi F., Ferri A., Casciati A., D'Ambrosi N., Rotilio G., Costa A., Volonte C., and Carri M.T. Overexpression of superoxide dismutase 1 protects against beta-amyloid peptide toxicity: effect of estrogen and copper chelators. Neurochem. Int. 44 (2004) 25-33
113. Troy C.M., Rabacchi S.A., Friedman W.J., Frappier T.F., Brown K., and Shelanski M.L. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J. Neurosci. 20 (2000) 1386-1392
114. Rohn T.T., Head E., Nesse W.H., Cotman C.W., and Cribbs D.H. Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol. Dis. 8 (2001) 1006-1016
115. Iwata N., Tsubulki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., Gerard C., Hama E., Lee H.J., and Saido T.C. Metabolic regulation of brain Abeta by neprilysin. Science 292 (2001) 1550-1552
116. Farris W., Mansourian S., Chang Y., Lindsley L., Eckamn E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., and Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 4162-4167
117. Hersh L.B. Peptidases, proteases and amyloid beta-peptide catabolism. Curr. Pharm. Des. 9 (2003) 449-454
118. Song E.S., and Hersh L.B. Insulysin: an allosteric enzyme as a target for Alzheimer's disease. J. Mol. Neurosci. 25 (2005) 201-206
119. Smith M.A., Dunbar C.E., Miller E.J., and Perry G. Trypsin interaction with the senile plaques of Alzheimer disease is mediated by beta-protein precursor. Mol. Chem. Neuropathol. 27 (1996) 145-154
120. Smith M.A., Kalaria R.N., and Perry G. Alpha 1-trypsin immunoreactivity in Alzheimer disease. Biochem. Biophys. Res. Commun. 193 (1993) 579-584
121. Chauhan V., Sheikh A.M., Chauhan A., Spivack W.D., Fenko M.D., and Malik M.N. Fibrillar amyloid beta-protein inhibits the activity of high molecular weight brain protease and trypsin. J. Alzheimers Dis. 7 (2005) 37-44
122. Butterfield D.A., Yatin S.M., Varadarajan S., and Koppal T. Amyloid beta-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer's disease. Methods Enzymol. 309 (1999) 746-768
123. Smith M.A., Rottkamp C.A., Nunomura A., Raina A.K., and Perry G. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502 (2000) 139-144
124. Butterfield D.A., Drake J., Pocernich C., and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7 (2001) 548-554
125. Butterfield D.A. Amyloid beta-peptide [1-42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. Curr. Med. Chem. 10 (2003) 2651-2659
126. Pogocki D. Alzheimer's beta-amyloid peptide as a source of neurotoxic free radicals: the role of structural effects. Acta Neurobiol. Exp. 63 (2003) 131-145
127. Shringarpure R., Grune T., Sitte N., and Davies K.J. 4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease. Cell Mol. Life Sci. 57 (2000) 1802-1809
128. Chander H.C., Chauhan A., Wegiel J., Malik M., Sheikh A., and Chauhan V. Binding of trypsin to fibrillar amyoid beta-protein. Brain Res. 1082 (2006) 173-181
129. Summers W.K. Alzheimer's disease, oxidative injury, and cytokines. J. Alzheimers Dis. 6 (2004) 651-657
130. Conte V., Uryu K., Fujimoto S., Yao Y., Rokach J., Longhi L., Trojanowski J.Q., Lee V.M., McIntosh T.K., and Pratico D. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J. Neurochem. 90 (2004) 758-764
131. Roberts G.W., Gentleman S.M., Lynch A., and Graham D.I. Beta A4 amyloid protein deposition in brain after head trauma. Lancet 338 (1991) 1422-1423
132. Uryu K., Laurer H., McIntosh T., Pratico D., Martinez D., Leight S., Lee V.M., and Trojanowski J.Q. Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J. Neurosci. 22 (2002) 446-454
133. Gamblin T.C., King M.E., Kuret J., Berry R.W., and Binder L.I. Oxidative regulation of fatty acid-induced tau polymerization. Biochemistry 39 (2000) 14203-14210
134. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., and Cowburn R.F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58 (1999) 1010-1019
135. Iqbal K., and Grundke-Iqbal I. Pharmacological approaches of neurofibrillary degeneration. Curr. Alzheimer Res. 2 (2005) 335-341
136. Gong C.X., Shaikh S., Wang J.Z., Zaidi T., Grundke-Iqbal I., and Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J. Neurochem. 65 (1995) 732-738
137. Lovell M.A., Xiong S., Xie C., Davies P., and Markesbery W.R. Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J. Alzheimers Dis. 6 (2004) 659-671
138. Yan S.D., Yan S.F., Chen X., Fu J., Chen M., Kuppusamy P., Smith M.A., Perry G., Godman G.C., and Nawroth P. Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat. Med. 1 (1995) 693-699
139. Egana J.T., Zambrano C., Nunez M.T., Gonzalez-Billault C., and Maccioni R.B. Iron-induced oxidative stress modify tau phosphorylation patterns in hippocampal cell cultures. Biometals 16 (2003) 215-223
140. Zambrano C.A., Egana J.T., Nunez M.T., Maccioni R.B., and Gonzalez-Billault C. Oxidative stress promotes tau dephosphorylation in neuronal cells: the roles of cdk5 and PP1. Free Radic. Biol. Med. 36 (2004) 1393-1402
141. Chauhan A., Ray I., and Chauhan V.P. Interaction of amyloid beta-protein with anionic phospholipids: possible involvement of Lys28 and C-terminus aliphatic amino acids. Neurochem. Res. 25 (2000) 423-429
142. Mar Martinez-Senac M., Villalain J., and Gomez-Fernandez J.C. Structure of the Alzheimer beta-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur. J. Biochem. 265 (1999) 744-753
143. Terzi E., Holzemann G., and Seelig J. Alzheimer beta-amyloid peptide 25-35: electrostatic interactions with phospholipid membranes. Biochemistry 33 (1994) 7434-7441
144. Jain S.K. The accumulation of malonyldialdehyde, a product of fatty acid peroxidation, can disturb aminophospholipid organization in the membrane bilayer of human erythrocytes. J. Biol. Chem. 259 (1984) 3391-3394
145. Jain S.K., Palmer M., and Chen Y. Effect of Vitamin E and N-acetylcysteine on phosphatidylserine externalization and induction of coagulation by high-glucose-treated human erythrocytes. Metabolism 48 (1999) 957-959
146. Jain S.K. Elevated malonyldialdehyde levels, altered membrane lipid asymmetry, and hypercoagulability of erythrocytes from newborn infants. Biomed. Biochim. Acta. 46 (1987) S21-S25
147. Jain S.K. In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats. J. Clin. Invest. 76 (1985) 281-286
148. Chong Z.Z., Li F., and Maiese K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res. Brain Res. Rev. 49 (2005) 1-21
149. Moreira P.I., Oliveira C.R., Santos M.S., Nunomura A., Honda K., Zhu X., Smith M.A., and Perry G. A second look into the oxidant mechanisms in Alzheimer's disease. Curr. Neurovasc. Res. 2 (2005) 179-184
150. Ayasolla K., Khan M., Singh A.K., and Singh I. Inflammatory mediator and beta-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by Vitamin E. Free Radic. Biol. Med. 37 (2004) 325-338
151. Yoon I., Lee K.H., and Cho J. Gossypin protects primary cultured rat cortical cells from oxidative stress- and beta-amyloid-induced toxicity. Arch. Pharm. Res. 27 (2004) 454-459
152. Zatta P., Tognon G., and Carampin P. Melatonin prevents free radical formation due to the interaction between beta-amyloid peptides and metal ions [Al(III), Zn(II), Cu(II), Mn(II), Fe(II)]. J. Pineal Res. 35 (2003) 98-103
153. Shishodia S., Sethi G., and Aggarwal B.B. Curcumin: getting back to the roots. Ann. N. Y. Acad. Sci. 1056 (2005) 206-217
154. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., and Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21 (2001) 8370-8377
155. DeFeudis F.V. Bilobalide and neuroprotection. Pharmacol. Res. 46 (2002) 565-568
156. Oken B.S., Storzbach D.M., and Kaye J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol. 55 (1998) 1409-1415
157. Yao Z., Drieu K., and Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 889 (2001) 181-190
158. Le Bars P.L. Response patterns of EGB 761 in Alzheimer's disease: influence of neuropsychological profiles. Pharmacopsychiatry 36 Suppl. 1 (2003) S50-S55
159. Schneider L.S., DeKosky S.T., Farlow M.R., Tariot P.N., Hoerr R., and Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr. Alzheimer Res. 2 (2005) 541-551
160. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., and Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336 (1997) 1216-1222
161. Petersen R.C., Thomas R.G., Grundman M., Bennett D., Doody R., Ferris S., Galacko D., Jin S., Kaye J., Levey A., Pfeiffer E., Sano M., van Dyck C.H., and Thal L.J. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352 (2005) 2379-2388
162. Gutzmann H., and Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J. Neural Trans. Suppl. 54 (1998) 301-310
163. Thal L.J., Carta A., Clarke W.R., Ferris S.H., Friedland R.P., Petersen R.C., Pettegrew J.W., Pfeiffer E., Raskind M.A., Sano M., Tuszynski M.H., and Woolson R.F. A 1-year multicenter placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer's disease. Neurology 47 (1996) 705-711
164. Ringman J.M., Frautschy S.A., Cole G.M., Masterman D.L., and Cummings J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer Res. 2 (2005) 131-136
165. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., and Cole G.M. Curcumin inhibits formation of amyloid {beta} oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280 (2005) 5892-5901
166. Cole G.M., Lim G.P., Yang F., Teter B., Begum A., Ma Q., Harris-White M.E., and Frautschy S.A. Prevention of Alzheimer's disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol. Aging 26 (2005) 133-136
167. Chauhan N., Wang K.C., Wegiel J., and Malik M.N. Walnut extract inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Curr. Alzheimer Res. 1 (2004) 183-188
168. Heo H.J., Kim D.O., Shin S.C., Kim M.J., Kim B.G., and Shin D.H. Effect of antioxidant flavanone, naringenin, from Citrus junoson neuroprotection. J. Agric. Food Chem. 52 (2004) 1520-1525